Publication | Closed Access

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways

Tumor BiologyTrk InhibitorMedicineTrk PathwaysReceptor Tyrosine KinasePharmacologyAntitumor EfficacyMolecular OncologyAnti-cancer AgentCancer BiologyCell BiologyCell SignalingCancer Research